Graves病患者^(131)I治疗前后TRAb、TGA和TMA的动态变化  

Study of TRAb, TGA and TMA Level Fluctuation in Patients with Graves′ Disease Before and After ^(131)I Therapy

作　　者：刘文豹[1] 刘杰[1] 

机构地区：[1]内蒙古医学院第三附属医院,内蒙包头014010

出　　处：《标记免疫分析与临床》2003年第4期216-218,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：通过测定Graves病患者1 3 1 I治疗前后血清TRAb、TGA、TMA含量变化 ,探讨TRAb、TGA和TMA在治疗Graves病过程中的价值。对Graves病患者1 3 1 I治疗前及治疗后 3、6、1 2和 1 8个月的血清TRAb、TGA和TMA水平进行测量。TRAb含量在治疗后 3、6个月明显升高 ,1 2个月明显降低 ,1 8个月后降至正常。TGA和TMA含量治疗后 3个月略微降低 ,6个月升高 ,1 2个月降低 ,1 8个月明显降低。动态观察Graves病患者1 3 1 I治疗前后血清TRAb、TGA和TMA含量变化可以观察疗效、指导治疗、预测复发。To determine the serum levels of TRAb, TGA and TMA in patients with Graves′ disease before and after 131 I therapy, serum levels of TRAb, TGA and TMA were measured by RIA in 132 patients before therapy and after therapy 3,6,12,18 months respectively.The levels of TRAb, TGA and TMA in the patients were significantly higher than those in the controls.After treatment, TRAb increased ( P <0.01) in the 3rd, 6th month, then decreased in the 12th month( P <0.05), and reached the normal in the 18th month. The levels of TGA and TMA decreased in the 3rd month after treatment, however, began to go up in the 6th month, and then dropped to the lower level in the 12th, 18th month compared to pre-therapy( P <0.01).The dynamical measurement of TRAb, TGA and TMA levels in patients with Graves′ disease is benificial to monitor treatements and predict prognosis.

关 键 词：GRAVES病 ^131I治疗 促甲状腺激素受体抗体 甲状腺球蛋白抗体 甲状腺微粒体抗体 

分 类 号：R581.1[医药卫生—内分泌]